Erythromelalgia (Investigational)
Highly investigational use for primary or secondary erythromelalgia (red, hot, painful extremities); no clinical study of leech therapy was identified.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for erythromelalgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is highly investigational.
- What evidence exists?
- Tier C (highly investigational). No clinical study or case report of leech therapy for erythromelalgia was identified, and there are no randomized controlled trials. Erythromelalgia management depends on etiology: aspirin for myeloproliferative-neoplasm-associated forms (must rule out JAK2 V617F mutation), sodium channel blockers (mexiletine, lidocaine) for SCN9A and primary forms, gabapentinoids for neuropathic pain, cooling and avoidance of triggers. Aspirin use in MPN-associated forms is itself an exclusion for leech therapy, creating practical incompatibility.
- Main risks
- Tissue breakdown or non-healing wounds in already fragile, hyperemic, painful skin
- Bleeding from bite sites for 6 to 24 hours after detachment
- Worsening of the pain or erythema in the first 24 hours
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
- Missing the diagnosis of a myeloproliferative neoplasm that requires hematology management
- Delay or replacement of evidence-based pharmacotherapy
- Who should not consider this
- Patients with MPN-associated erythromelalgia who should be on aspirin
- Patients on anticoagulants (aspirin and clopidogrel, alone or together, are not a contraindication by themselves: tell your doctor, who starts with fewer leeches)
- Patients with an active SCN9A pain crisis (sodium channel blocker first)
- Patients with concurrent skin breakdown in the affected area
- Patients with cooling-responsive symptoms who have not tried conventional medications
- Patients with anemia, hemophilia, or active infection
- What to ask your clinician
- Has my erythromelalgia been classified as primary (SCN9A or idiopathic) or secondary (MPN, autoimmune, drug-related)?
- Has a hematology workup been completed (CBC, JAK2 V617F, peripheral smear)?
- Have I tried aspirin (if MPN-associated), mexiletine, lidocaine patches, or gabapentinoids?
- What are my known triggers, and what is my cooling and trigger-avoidance plan?
- Has the practitioner explained why leech therapy is incompatible with aspirin in MPN-associated forms?
- What is the realistic expectation of benefit, and what is the duration?
- What is the practitioner's experience and Aeromonas-prevention plan?
- When to seek urgent care
- Sudden severe burning pain with skin breakdown, ulceration, or blackening (tissue breakdown — urgent care)
- New unilateral arm or leg swelling (DVT in MPN-associated forms)
- Sudden chest pain, shortness of breath, or stroke-like symptoms (thrombotic event)
- Spreading redness, pus, or red streaks (cellulitis or wound infection)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for erythromelalgia.
- The absence of any clinical study means efficacy versus aspirin (MPN-associated forms) or sodium-channel blockers has NOT been established.
- Mechanism rationale (anti-inflammation, microvascular) does NOT address SCN9A channelopathy or MPN thrombosis risk.
- Leech therapy is incompatible with aspirin, which is a key therapy in MPN-associated forms.
- Leech therapy is not a substitute for hematology workup or evidence-based pharmacotherapy.
Safety cross-references
Clinical Profile
- Category
- Vascular
- ICD-10
- I73.81
- Safety tier
- High
Evidence Summary
Erythromelalgia is a rare disorder of episodic erythema, warmth, and burning pain in extremities, classified as primary (often SCN9A mutation) or secondary (myeloproliferative neoplasms, autoimmune disease). Conventional management includes cooling, aspirin (responsive in MPN-associated forms), sodium channel blockers (mexiletine, lidocaine), and gabapentinoids. No modern clinical study or case report of leech therapy for erythromelalgia was identified in PubMed, in Europe PMC titles and abstracts, or in Russian-language sources; a 2025 historical review (Eaton and Mayrovitz, Cureus, PMID 40062126) mentions leech application among numerous experimental treatments in early single case reports, with unclear therapeutic value; use is investigational and mechanistic only. A practical incompatibility also exists: aspirin responsiveness in MPN-associated forms implicates platelet involvement, yet ongoing aspirin or antiplatelet use is an exclusion for leech therapy.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active deep vein thrombosis (acute phase)
- Critical limb ischemia (ABI <0.4)
- MPN-associated erythromelalgia requiring aspirin
- Active SCN9A pain crisis (consider sodium channel blocker first)
- Concurrent skin breakdown in affected area
- Cooling-responsive symptoms without medication trial
Related Conditions
Raynaud's Syndrome (Primary)
Investigational use for primary Raynaud's phenomenon; the only clinical report is three patients in a 2025 Azerbaijani case series, with no controlled trial.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.
Complex Regional Pain Syndrome (Type I, Investigational)
Highly investigational adjunct for CRPS Type I; one case report and no controlled study identified; multidisciplinary pain management and physiotherapy remain primary.
Chronic Venous Insufficiency (CEAP C3-C5)
Off-label adjunct to compression; the journal evidence is one small open-label randomized trial in varicose veins (n=50) and a 20-patient uncontrolled series; the books describe further reports (see “What the books describe” below).